Uroplakin II outperforms uroplakin III in diagnostically challenging settings
Aims We performed a head‐to‐head comparison of an antibody against uroplakin III (UP3) and a new uroplakin II (UP2) antibody that remains untested in diagnostically challenging settings. Methods and results We immunostained high‐grade bladder neck carcinomas (n = 35), high‐grade upper tract urotheli...
Gespeichert in:
Veröffentlicht in: | Histopathology 2014-07, Vol.65 (1), p.132-138 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Aims
We performed a head‐to‐head comparison of an antibody against uroplakin III (UP3) and a new uroplakin II (UP2) antibody that remains untested in diagnostically challenging settings.
Methods and results
We immunostained high‐grade bladder neck carcinomas (n = 35), high‐grade upper tract urothelial carcinomas (UC) and renal carcinomas (n = 85), metastases of UC (n = 30) and a multicancer tissue microarray (n = 88) for UP3 and UP2, and scored staining intensity and proportion. UP3 showed membranous plaque‐like expression, while UP2 staining showed both membranous and cytoplasmic positivity. Significantly greater intensity (P = 0.003) and proportion (P = 0.03) of staining was noted for UP2 among bladder neck lesions, with UP2 staining showing greater sensitivity (63% versus 19%) and similar specificity (95% versus 100%) for UC over prostate carcinoma (P = 0.02). Among upper tract lesions, UP2 staining showed greater intensity and proportion than UP3 (both P |
---|---|
ISSN: | 0309-0167 1365-2559 |
DOI: | 10.1111/his.12360 |